课题基金 / 基金详情

PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT

PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT
3 期 AML：柔红霉素剂量加强
批准号：
7625776
负责人：
Witold B. Rybka
金额：
$3.01万
依托单位：
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-04-01 至 2008-03-31
来源：
https://reporter.nih.gov/project-details/7625776
关键词：
AutologousComputer Retrieval of Information on Scientific Projects DatabaseDaunorubicinDisease-Free SurvivalDoseFundingGemtuzumab OzogamicinGrantInstitutionPeripheral Blood Stem CellPhaseProtocols documentationResearchResearch PersonnelResourcesSourceStem cell transplantTransplantationUnited States National Institutes of Health

项目摘要

项目成果

Witold B. Rybka的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该方案的主要目的是比较两种巩固方案之间的无病生存(DFS)：吉珠单抗-奥佐格米星联合自体外周血干细胞(PBSC)移植或直接自体移植。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to compare disease-free survival (DFS) between two consolidation regimes: Gemtuzumab-ozogamicin followed by autologous peripheral blood stem cell (PBSC) transplant or directly to autologous transplant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET
CLINICAL TRIAL: A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION
CLINICAL TRIAL: PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL